Analysis of monosomy-3 in immunomagnetically isolated circulating melanoma cells in uveal melanoma patients

2016 ◽  
Vol 29 (5) ◽  
pp. 583-589 ◽  
Author(s):  
Aysegül Tura ◽  
Hartmut Merz ◽  
Mihaela Reinsberg ◽  
Matthias Lüke ◽  
Martine J. Jager ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Melanoma Cells ◽  
Monosomy 3 ◽  
Melanoma Patients

Abstract 384: Detection of circulating melanoma cells in paired arterial and venous specimens from uveal melanoma patients with hepatic metastatic

2015 ◽  
Author(s):  
Mizue Terai ◽  
Zhaomei Mu ◽  
David Eschelman ◽  
Carin Gonsalves ◽  
Ken Kageyama ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Melanoma Cells ◽  
Melanoma Patients

Higher Percentage of FISH-Determined Monosomy 3 and 8q Amplification in Uveal Melanoma Cells relate to Poor Patient Prognosis

2012 ◽  
Vol 53 (6) ◽  
pp. 2668 ◽  
Author(s):  
Thomas van den Bosch ◽  
Jackelien G. M. van Beek ◽  
Jolanda Vaarwater ◽  
Robert M. Verdijk ◽  
Nicole C. Naus ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Melanoma Cells ◽  
Poor Patient ◽  
Monosomy 3 ◽  
Patient Prognosis

Identification of Circulating Melanoma Cells in Uveal Melanoma Patients by Dual-Marker Immunoenrichment

2014 ◽  
Vol 55 (7) ◽  
pp. 4395 ◽  
Author(s):  
Aysegül Tura ◽  
Julia Lüke ◽  
Hartmut Merz ◽  
Mihaela Reinsberg ◽  
Matthias Lüke ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Melanoma Cells ◽  
Melanoma Patients

Adjuvant sunitinib in high-risk patients with uveal melanoma: A pilot study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 8560-8560
Author(s):  
Matias Emanuel Valsecchi ◽  
Nancy Shockley ◽  
Deborah Summers ◽  
Carol L Shields ◽  
Jerry A Shields ◽  
...  
Keyword(s):  
Pilot Study ◽  
High Risk ◽  
Uveal Melanoma ◽  
Death Rate ◽  
Large Tumor ◽  
Primary Tumors ◽  
High Risk Patients ◽  
Monosomy 3 ◽  
Risk Patients ◽  
Melanoma Patients

8560 Background: Uveal melanoma is the most common primary intraocular cancer in adults. Despite the successful treatments for primary tumors, up to 50% of the patients later die of distant metastases. Currently no effective adjuvant treatment is available for these patients. Our group previously reported that sunitinib stabilized systemic metastases in 65% of uveal melanoma patients who failed prior treatments. In this pilot study, we tested sunitinib in an adjuvant setting in high-risk patients with primary uveal melanoma. Methods: Patients with estimated metastatic death rate ≥ 50% based on the following criteria were eligible: (1) monosomy 3 and 8q amplification; (2) large tumor (≥ 15 mm in diameter and ≥7 mm in thickness); (3) monosomy 3 and other risk factors (large tumor, epithelioid dominant cell type, local recurrence, or extra-scleral extension). Sunitinib was given at 25 mg PO daily for at least 6 months. Primary endpoint was disease-free survival (DFS) and overall survival (OS), estimated with Kaplan-Meier analysis (SPSS 17.0). Secondary endpoint was safety. Results: A total of 23 Caucasian patients (median, 54 years; range: 25 – 77) were enrolled. All patients received sunitinib for at least 6 months (range: 6 – 12). Eighteen patients had confirmed monosomy 3, from whom 13 (72%) also showed 8q amplification. The median follow-up was 24 months (range 12 – 54 months). Only one patient died of unknown cause (OS: 30.4 months). A total of seven patients (30%) developed systemic metastases, all of which were liver metastases. The DFS and OS rates at 2 years were 70% (95% CI: 47 – 86%) and 100%, respectively. The OS rate at 2 years was better than historical control with monosomy 3 patients (51%, 95% CI: 31 – 71%) (Invest Ophthalmol Vis Sci 2003; 44:1008). In those patients who relapsed, the median time to progression after finishing sunitinib was 2 months (range: 0 – 8). The most common adverse events were: diarrhea (47%), fatigue (39%), dermatitis (30%), stomatitis (13%), leucopenia (8%), and nausea (4%). Most were grade 1 or 2 (88%) and only one was considered grade 4 (diarrhea). Conclusions: In high-risk uveal melanoma patients with estimated metastatic death rate of ≥ 50%, adjuvant sunitinib showed promising results and deserves further investigation.

scholarly journals Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors

2021 ◽  
Vol 10 (8) ◽  
pp. 2618-2626
Author(s):  
Michael S. Sander ◽  
Igor Stukalin ◽  
Isabelle A. Vallerand ◽  
Siddhartha Goutam ◽  
Benjamin W. Ewanchuk ◽  
...  
Keyword(s):  
Uveal Melanoma ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Prognostic Index ◽  
Melanoma Patients

scholarly journals The Efficacy of Anti-PD-L1 Treatment in Melanoma Is Associated with the Expression of the ECM Molecule EMILIN2

2021 ◽  
Vol 22 (14) ◽  
pp. 7511
Author(s):  
Albina Fejza ◽  
Maurizio Polano ◽  
Lucrezia Camicia ◽  
Evelina Poletto ◽  
Greta Carobolante ◽  
...  
Keyword(s):  
Gene Expression ◽  
Effective Treatment ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Tumor Hypoxia ◽  
Melanoma Cells ◽  
Vessel Normalization ◽  
Melanoma Patients

The use of immune checkpoint inhibitors has revolutionized the treatment of melanoma patients, leading to remarkable improvements in the cure. However, to ensure a safe and effective treatment, there is the need to develop markers to identify the patients that would most likely respond to the therapies. The microenvironment is gaining attention in this context, since it can regulate both the immunotherapy efficacyand angiogenesis, which is known to be affected by treatment. Here, we investigated the putative role of the ECM molecule EMILIN-2, a tumor suppressive and pro-angiogenic molecule. We verified that the EMILIN2 expression is variable among melanoma patients and is associated with the response to PD-L1 inhibitors. Consistently, in preclinical settings,the absence of EMILIN-2 is associated with higher PD-L1 expression and increased immunotherapy efficacy. We verified that EMILIN-2 modulates PD-L1 expression in melanoma cells through indirect immune-dependent mechanisms. Notably, upon PD-L1 blockage, Emilin2−/− mice displayed improved intra-tumoral vessel normalization and decreased tumor hypoxia. Finally, we provide evidence indicating that the inclusion of EMILIN2 in a number of gene expression signatures improves their predictive potential, a further indication that the analysis of this molecule may be key for the development of new markers to predict immunotherapy efficacy.

scholarly journals Digital morphometry of tumor nuclei correlates to BAP-1 status, monosomy 3, gene expression class and survival in uveal melanoma

2020 ◽  
Vol 193 ◽  
pp. 107987
Author(s):  
Christina Herrspiegel ◽  
Thonnie Rose O. See ◽  
Pia R. Mendoza ◽  
Hans E. Grossniklaus ◽  
Gustav Stålhammar
Keyword(s):  
Gene Expression ◽  
Uveal Melanoma ◽  
Monosomy 3
Sign in / Sign up

Export Citation Format

Share Document